STAGE III BLADDER CANCER AJCC V8
Clinical trials for STAGE III BLADDER CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III BLADDER CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III BLADDER CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Bladder-Sparing cancer combo aims to boost cure rates
Disease control OngoingThis study is testing whether adding a drug called durvalumab (an immunotherapy) to standard chemotherapy and radiation works better for treating bladder cancer that has spread to nearby lymph nodes. The main goal is to see if more patients achieve a complete response, meaning no…
Matched conditions: STAGE III BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 04, 2026 02:05 UTC
-
New combo therapy trial offers hope for Tough-to-Treat bladder cancer
Disease control OngoingThis study is testing whether adding a chemotherapy drug (eribulin) to an immunotherapy drug (atezolizumab) works better than the immunotherapy drug alone for people with advanced bladder cancer that has spread or come back. It is for patients who cannot take a standard chemother…
Matched conditions: STAGE III BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Personalized cancer fight: matching drugs to your Tumor's genetic fingerprint
Disease control OngoingThis study is testing whether specific genetic markers in a patient's tumor can predict if they will respond well to immunotherapy drugs. It is for people with advanced bladder cancer that has spread and has stopped responding to standard chemotherapy. Participants receive two im…
Matched conditions: STAGE III BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
Scientists test Triple-Threat drug combo against Tough-to-Treat cancers
Disease control OngoingThis early-stage study is testing the safety and best doses of a combination of cancer drugs for people with advanced cancers of the urinary system (like bladder and kidney cancer) that have spread. The trial combines a pill (cabozantinib) that aims to block tumor growth with one…
Matched conditions: STAGE III BLADDER CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New drug duo tested for Tough-to-Treat bladder cancer
Disease control OngoingThis study is testing a new combination of two drugs, tazemetostat and pembrolizumab, for people with advanced bladder cancer that has spread or is resistant to standard chemotherapy. The main goals are to find the safest dose and see if the combination helps control the cancer b…
Matched conditions: STAGE III BLADDER CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New drug combo aims to keep advanced bladder cancer at bay
Disease control OngoingThis large, late-stage trial is testing if adding a pill called cabozantinib to an immunotherapy drug (avelumab) is better than the immunotherapy alone for keeping advanced bladder cancer from growing or returning. It is for patients whose cancer did not worsen after their first …
Matched conditions: STAGE III BLADDER CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
Targeted drug combo tested to fight tough bladder cancer
Disease control TerminatedThis study aimed to see if a targeted pill (erdafitinib) alone or combined with an immunotherapy drug (atezolizumab) could shrink aggressive bladder tumors before surgery. It was for patients whose cancer had grown into the muscle wall of the bladder and who could not receive the…
Matched conditions: STAGE III BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC
-
New cancer combo aims to supercharge immune system while taming side effects
Disease control OngoingThis study is testing a combination of three immunotherapy drugs—tocilizumab, ipilimumab, and nivolumab—in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. The main goal is to see if adding tocilizumab can help manage the serious side effects someti…
Matched conditions: STAGE III BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC